Michael Meyring

682 total citations
17 papers, 455 citations indexed

About

Michael Meyring is a scholar working on Hepatology, Oncology and Biomedical Engineering. According to data from OpenAlex, Michael Meyring has authored 17 papers receiving a total of 455 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hepatology, 5 papers in Oncology and 4 papers in Biomedical Engineering. Recurrent topics in Michael Meyring's work include Liver physiology and pathology (7 papers), Microfluidic and Capillary Electrophoresis Applications (4 papers) and Innovative Microfluidic and Catalytic Techniques Innovation (3 papers). Michael Meyring is often cited by papers focused on Liver physiology and pathology (7 papers), Microfluidic and Capillary Electrophoresis Applications (4 papers) and Innovative Microfluidic and Catalytic Techniques Innovation (3 papers). Michael Meyring collaborates with scholars based in Germany, Italy and Switzerland. Michael Meyring's co-authors include Gottfried Blaschke, Bezhan Chankvetadze, Frank Stieber, Dieter Dorsch, Andree Blaukat, Oliver Schadt, Manja Friese‐Hamim, Friedhelm Bladt, Ulrich Grädler and Ulrich Pehl and has published in prestigious journals such as Analytical Chemistry, Cancer Research and Clinical Cancer Research.

In The Last Decade

Michael Meyring

17 papers receiving 444 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Meyring Germany 10 159 153 131 96 92 17 455
Gek San Tan Singapore 12 346 2.2× 101 0.7× 80 0.6× 54 0.6× 101 1.1× 19 709
Lance Goulet United States 11 379 2.4× 41 0.3× 26 0.2× 20 0.2× 81 0.9× 14 639
Changcheng Wang China 15 284 1.8× 113 0.7× 37 0.3× 12 0.1× 100 1.1× 38 738
Brooke M. Rock United States 17 370 2.3× 48 0.3× 96 0.7× 10 0.1× 204 2.2× 29 780
Simonetta Andrea Licandro Italy 11 186 1.2× 98 0.6× 32 0.2× 5 0.1× 120 1.3× 22 462
Masahiro Kito Japan 9 188 1.2× 36 0.2× 21 0.2× 130 1.4× 77 0.8× 18 419
Jaap Verweij Netherlands 10 255 1.6× 33 0.2× 37 0.3× 15 0.2× 387 4.2× 10 587
Tarundeep Kakkar United States 10 252 1.6× 20 0.1× 16 0.1× 31 0.3× 94 1.0× 18 538
U. Holwerda Netherlands 10 254 1.6× 21 0.1× 38 0.3× 9 0.1× 216 2.3× 13 572

Countries citing papers authored by Michael Meyring

Since Specialization
Citations

This map shows the geographic impact of Michael Meyring's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Meyring with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Meyring more than expected).

Fields of papers citing papers by Michael Meyring

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Meyring. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Meyring. The network helps show where Michael Meyring may publish in the future.

Co-authorship network of co-authors of Michael Meyring

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Meyring. A scholar is included among the top collaborators of Michael Meyring based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Meyring. Michael Meyring is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Dorsch, Dieter, Oliver Schadt, Frank Stieber, et al.. (2015). Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 25(7). 1597–1602. 68 indexed citations
3.
Bawab, Samer El, Friedhelm Bladt, Michael Meyring, et al.. (2015). Abstract 4510: Model-based phase II dose selection of c-Met inhibitor MSC2156119J. Cancer Research. 75(15_Supplement). 4510–4510. 2 indexed citations
4.
Hoppe, Edmund, Nicola J. Hewitt, Hans‐Peter Buchstaller, et al.. (2014). A Novel Strategy for ADME Screening of Prodrugs: Combined Use of Serum and Hepatocytes to Integrate Bioactivation and Clearance, and Predict Exposure to Both Active and Prodrug to the Systemic Circulation. Journal of Pharmaceutical Sciences. 103(5). 1504–1514. 8 indexed citations
5.
Bladt, Friedhelm, Manja Friese‐Hamim, Christine Knuehl, et al.. (2013). EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors. Clinical Cancer Research. 19(11). 2941–2951. 114 indexed citations
6.
Geißler, Simon, et al.. (2013). In vitro–in vivo evaluation of nanosuspension release from subcutaneously implantable osmotic pumps. International Journal of Pharmaceutics. 451(1-2). 57–66. 9 indexed citations
7.
Hagen, Timo L.M. ten, Ann L.B. Seynhaeve, E. A. de Bruijn, et al.. (2012). The αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model. International Journal of Cancer. 132(11). 2694–2704. 11 indexed citations
8.
Bladt, Friedhelm, Andree Blaukat, Dieter Dorsch, et al.. (2011). Abstract 2786: Identification and preclinical characterization of EMD 1204831 – A selective c-Met kinase inhibitor in clinical phase 1. Cancer Research. 71(8_Supplement). 2786–2786. 2 indexed citations
9.
Bladt, Friedhelm, Andree Blaukat, Dieter Dorsch, et al.. (2010). Abstract 3622: Preclinical characterization of EMD1214063, a potent and highly selective inhibitor of the c-Met kinase in Phase I clinical trials. Cancer Research. 70(8_Supplement). 3622–3622. 4 indexed citations
10.
Schadt, Oliver, Dieter Dorsch, Frank Stieber, et al.. (2010). 216 Preclinical characterization of EMD 1214063 - a selective c-Met kinase inhibitor in clinical phase 1. European Journal of Cancer Supplements. 8(7). 71–71. 1 indexed citations
11.
Schadt, Oliver, Friedhelm Bladt, Andree Blaukat, et al.. (2010). Abstract 5777: EMD 1214063, an exquisitely selective c-Met kinase inhibitor in clinical phase 1. Cancer Research. 70(8_Supplement). 5777–5777. 1 indexed citations
12.
13.
Meyring, Michael, Jörg Mühlbacher, Kim Messer, et al.. (2002). In Vitro Biotransformation of (R)-and (S)-Thalidomide:  Application of Circular Dichroism Spectroscopy to the Stereochemical Characterization of the Hydroxylated Metabolites. Analytical Chemistry. 74(15). 3726–3735. 41 indexed citations
14.
15.
Meyring, Michael, et al.. (2000). Investigation of the stereoselectivein vitro biotransformation of thalidomide using a dual cyclodextrin system in capillary electrophoresis. Electrophoresis. 21(15). 3270–3279. 24 indexed citations
16.
Meyring, Michael, Dirk B Strickmann, Bezhan Chankvetadze, et al.. (1999). Investigation of the in vitro biotransformation of R-(+)-thalidomide by HPLC, nano-HPLC, CEC and HPLC–APCI-MS. Journal of Chromatography B Biomedical Sciences and Applications. 723(1-2). 255–264. 29 indexed citations
17.
Meyring, Michael, Bezhan Chankvetadze, & Gottfried Blaschke. (1999). Enantioseparation of thalidomide and its hydroxylated metabolites using capillary electrophoresis with various cyclodextrins and their combinations as chiral buffer additives. Electrophoresis. 20(12). 2425–2431. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gek San Tan Breakdown of academic impact, for papers by Lance Goulet Breakdown of academic impact, for papers by Changcheng Wang Breakdown of academic impact, for papers by Brooke M. Rock Breakdown of academic impact, for papers by Simonetta Andrea Licandro Breakdown of academic impact, for papers by Masahiro Kito Breakdown of academic impact, for papers by Jaap Verweij Breakdown of academic impact, for papers by Tarundeep Kakkar Breakdown of academic impact, for papers by U. Holwerda
Rankless by CCL
2026